FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968971583> ?p ?o ?g. }

• W2968971583 abstract "Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of patients progress to incurable brain metastases due to acquired resistance and/or limited permeability of inhibitors across the blood-brain barrier. Neratinib, a potent irreversible pan-tyrosine kinase inhibitor, prolongs disease-free survival in the extended adjuvant setting, and several trials evaluating its efficacy alone or combination with other inhibitors in early and advanced HER2-positive breast cancer patients are ongoing. However, its efficacy as a first-line therapy against HER2-positive breast cancer brain metastasis has not been fully explored, in part due to the lack of relevant pre-clinical models that faithfully recapitulate this disease. Here, we describe the development and characterisation of a novel syngeneic model of spontaneous HER2-positive breast cancer brain metastasis (TBCP-1) and its use to evaluate the efficacy and mechanism of action of neratinib.TBCP-1 cells were derived from a spontaneous BALB/C mouse mammary tumour and characterised for hormone receptors and HER2 expression by flow cytometry, immunoblotting and immunohistochemistry. Neratinib was evaluated in vitro and in vivo in the metastatic and neoadjuvant setting. Its mechanism of action was examined by transcriptomic profiling, function inhibition assays and immunoblotting.TBCP-1 cells naturally express high levels of HER2 but lack expression of hormone receptors. TBCP-1 tumours maintain a HER2-positive phenotype in vivo and give rise to a high incidence of spontaneous and experimental metastases in the brain and other organs. Cell proliferation/viability in vitro is inhibited by neratinib and by other HER2 inhibitors, but not by anti-oestrogens, indicating phenotypic and functional similarities to human HER2-positive breast cancer. Mechanistically, neratinib promotes a non-apoptotic form of cell death termed ferroptosis. Importantly, metastasis assays demonstrate that neratinib potently inhibits tumour growth and metastasis, including to the brain, and prolongs survival, particularly when used as a neoadjuvant therapy.The TBCP-1 model recapitulates the spontaneous spread of HER2-positive breast cancer to the brain seen in patients and provides a unique tool to identify novel therapeutics and biomarkers. Neratinib-induced ferroptosis provides new opportunities for therapeutic intervention. Further evaluation of neratinib neoadjuvant therapy is warranted." @default.
• W2968971583 created "2019-08-22" @default.
• W2968971583 creator A5001056403 @default.
• W2968971583 creator A5005089171 @default.
• W2968971583 creator A5007997858 @default.
• W2968971583 creator A5009131786 @default.
• W2968971583 creator A5010278367 @default.
• W2968971583 creator A5013611674 @default.
• W2968971583 creator A5015397173 @default.
• W2968971583 creator A5018022715 @default.
• W2968971583 creator A5019678559 @default.
• W2968971583 creator A5053116950 @default.
• W2968971583 creator A5070304067 @default.
• W2968971583 creator A5071441452 @default.
• W2968971583 creator A5071561870 @default.
• W2968971583 creator A5075151999 @default.
• W2968971583 creator A5084463756 @default.
• W2968971583 date "2019-08-13" @default.
• W2968971583 modified "2023-10-15" @default.
• W2968971583 title "Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis" @default.
• W2968971583 cites W1572693845 @default.
• W2968971583 cites W1597931794 @default.
• W2968971583 cites W1751006537 @default.
• W2968971583 cites W1976446970 @default.
• W2968971583 cites W1982093899 @default.
• W2968971583 cites W1986733915 @default.
• W2968971583 cites W1993598681 @default.
• W2968971583 cites W1997183854 @default.
• W2968971583 cites W2040935952 @default.
• W2968971583 cites W2057632732 @default.
• W2968971583 cites W2060199275 @default.
• W2968971583 cites W2060277971 @default.
• W2968971583 cites W2062126118 @default.
• W2968971583 cites W2063376924 @default.
• W2968971583 cites W2067973073 @default.
• W2968971583 cites W2074366436 @default.
• W2968971583 cites W2077515948 @default.
• W2968971583 cites W2098506409 @default.
• W2968971583 cites W2100662195 @default.
• W2968971583 cites W2101884133 @default.
• W2968971583 cites W2102278945 @default.
• W2968971583 cites W2114104545 @default.
• W2968971583 cites W2114138419 @default.
• W2968971583 cites W2114195503 @default.
• W2968971583 cites W2115759102 @default.
• W2968971583 cites W2115847479 @default.
• W2968971583 cites W2119547813 @default.
• W2968971583 cites W2135670695 @default.
• W2968971583 cites W2137586531 @default.
• W2968971583 cites W2138207763 @default.
• W2968971583 cites W2138851777 @default.
• W2968971583 cites W2139154837 @default.
• W2968971583 cites W2146384083 @default.
• W2968971583 cites W2149550866 @default.
• W2968971583 cites W2152855697 @default.
• W2968971583 cites W2155313869 @default.
• W2968971583 cites W2163432985 @default.
• W2968971583 cites W2263556989 @default.
• W2968971583 cites W2265062179 @default.
• W2968971583 cites W2289834888 @default.
• W2968971583 cites W2306887678 @default.
• W2968971583 cites W2327686392 @default.
• W2968971583 cites W2338611117 @default.
• W2968971583 cites W2405259065 @default.
• W2968971583 cites W2465328916 @default.
• W2968971583 cites W2471493685 @default.
• W2968971583 cites W2473406553 @default.
• W2968971583 cites W2488521558 @default.
• W2968971583 cites W2513656923 @default.
• W2968971583 cites W2548770983 @default.
• W2968971583 cites W2549188196 @default.
• W2968971583 cites W2549428458 @default.
• W2968971583 cites W2566407837 @default.
• W2968971583 cites W2584554595 @default.
• W2968971583 cites W2584922809 @default.
• W2968971583 cites W2592029987 @default.
• W2968971583 cites W2611815314 @default.
• W2968971583 cites W2613290044 @default.
• W2968971583 cites W2624067448 @default.
• W2968971583 cites W2734795522 @default.
• W2968971583 cites W2742734698 @default.
• W2968971583 cites W2743022421 @default.
• W2968971583 cites W2762797953 @default.
• W2968971583 cites W2768980003 @default.
• W2968971583 cites W2783665273 @default.
• W2968971583 cites W2794185840 @default.
• W2968971583 cites W2799868296 @default.
• W2968971583 cites W2883757758 @default.
• W2968971583 cites W2889646458 @default.
• W2968971583 cites W2895955393 @default.
• W2968971583 cites W2898173867 @default.
• W2968971583 cites W2951205131 @default.
• W2968971583 cites W2987064450 @default.
• W2968971583 cites W3016288444 @default.
• W2968971583 cites W4213437900 @default.
• W2968971583 cites W4233526312 @default.
• W2968971583 cites W4239989216 @default.
• W2968971583 doi "https://doi.org/10.1186/s13058-019-1177-1" @default.
• W2968971583 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6693253" @default.
• W2968971583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31409375" @default.

• next